RESUMO
BACKGROUND AND AIMS: Inborn errors of purine and pyrimidine metabolism are a diverse group of disorders with possible serious or life-threatening symptoms. They may be associated with neurological symptoms, renal stone disease or immunodeficiency. However, the clinical presentation can be nonspecific and mild so that a number of cases may be missed. Previously published assays lacked detection of certain diagnostically important biomarkers, including SAICAr, AICAr, beta-ureidoisobutyric acid, 2,8-dihydroxyadenine and orotidine, necessitating the use of separate assays for their detection. Moreover, the limited sensitivity for some analytes in earlier assays may have hampered the reliable detection of mild cases. Therefore, we aimed to develop a liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay that allows the simultaneous and sensitive detection of an extended range of purine and pyrimidine biomarkers in urine. METHODS: The assay was developed and validated using LC-MS/MS and clinically tested by analyzing ERNDIM Diagnostic Proficiency Testing (DPT) samples and further specimens from patients with various purine and pyrimidine disorders. RESULTS: Reliable determination of 27 analytes including SAICAr, AICAr, beta-ureidoisobutyric acid, 2,8-dihydroxyadenine and orotidine was achieved in urine following a simple sample preparation. The method clearly distinguished pathological and normal samples and differentiated between purine and pyrimidine defects in all clinical specimens. CONCLUSIONS: A LC-MS/MS assay allowing the simultaneous, sensitive and reliable diagnosis of an extended range of purine and pyrimidine disorders has been developed. The validated method has successfully been tested using ERNDIM Diagnostic Proficiency Testing (DPT) samples and further clinical specimens from patients with various purine and pyrimidine disorders. Sample preparation is simple and assay duration is short, facilitating an easier inclusion of the assay into the diagnostic procedures.
Assuntos
Cromatografia Líquida/métodos , Erros Inatos do Metabolismo da Purina-Pirimidina/diagnóstico , Erros Inatos do Metabolismo da Purina-Pirimidina/urina , Espectrometria de Massas em Tandem/métodos , Adenina/análogos & derivados , Adenina/urina , Adolescente , Adulto , Aminoimidazol Carboxamida/análogos & derivados , Aminoimidazol Carboxamida/urina , Biomarcadores/urina , Criança , Pré-Escolar , Cromatografia Líquida/normas , Cromatografia Líquida/estatística & dados numéricos , Feminino , Humanos , Lactente , Masculino , Controle de Qualidade , Valores de Referência , Ribonucleotídeos/urina , Espectrometria de Massas em Tandem/normas , Espectrometria de Massas em Tandem/estatística & dados numéricos , Ureia/análogos & derivados , Ureia/urina , Uridina/análogos & derivados , Uridina/urinaRESUMO
Both AICAR and mannitol are prohibited for use in sports, but no decisive criteria that would guide anti-doping laboratories on data interpretation have been established so far. In an attempt to help harmonize reporting and management of analytical findings, reference population data collected for US athletes are presented. Upon analysis of 12 377 samples, mean urinary AICAR concentration was found to be 647 ± 365 ng/mL with median value of 574 ng/mL, 99th percentile at 1786 ng/mL and 99.7th percentile at 2151 ng/mL. Based on these results, we suggest that any sample with AICAR concentration greater than 2000 or 2500 ng/mL be analyzed by carbon isotope ratio mass spectrometry to establish the origin. Urinary mannitol concentrations demonstrate larger variation with the mean value of 72 ± 140 µg/mL and median at 41 µg/mL (n = 6407). While the 99.7th percentile for mannitol was measured to be 1094 µg/mL, the population data alone is not sufficient to suggest a threshold value. It is also shown that the use of mannitol as a sweetener in amounts of up to 20 g per day results in a urinary concentration of about 14 mg/mL. As only intravenous mannitol is prohibited in sports, controlled excretion studies are needed to see whether intravenous administration could in fact be discriminated from dietary intake. An important observation is that mannitol present in mg/mL quantities significantly increases urine specific gravity, which makes a widely accepted normalization approach not applicable.
Assuntos
Aminoimidazol Carboxamida/análogos & derivados , Atletas , Dopagem Esportivo , Manitol/urina , Ribonucleotídeos/urina , Aminoimidazol Carboxamida/urina , Atletas/estatística & dados numéricos , Isótopos de Carbono , Dopagem Esportivo/métodos , Humanos , Espectrometria de Massas , Detecção do Abuso de Substâncias/métodosRESUMO
AIMS: 5-Aminoimidazole-4-carboxamide riboside (AICAR) is an endogenous activator of AMPK, a central regulator of energy homeostasis. Loss and/or reduction of AMPK signaling plays an important role in the development of insulin resistance in type 2 diabetes. The loss of AMPK in diabetes could be due to a loss of AICAR. The aim of this study was to characterize urine levels of AICAR in diabetes and determine whether an association exists with respect to late complications, e.g., retinopathy, nephropathy and neuropathy. METHODS: Urine AICAR was measured by liquid chromatography tandem mass spectrometry in 223 patients consisting of 5 healthy controls, 63 patients with pre-diabetes, 29 patients with newly diagnosed type 2 diabetes and 126 patients with long-standing type 2 diabetes. For statistical analyses, nonparametric Kruskal-Wallis test, one-way ANOVA and multivariate regression analysis were performed to investigate the associations of urinary AICAR excretion within different groups and different clinical parameters. RESULTS: The mean urine AICAR for all 223 patients was 694.7 ± 641.1 ng/ml. There was no significant difference in urine AICAR between the control and patients with diabetes (592.3 ± 345.1 vs. 697.1 ± 646.5 ng/ml). No association between any of the biochemical and/or clinical parameters measured and urine AICAR was found, with the exception of age of patient (R = - 0.34; p < 0.01) and estimated glomerular filtration rate (R = 0.19; p = 0.039). These results were confirmed additionally by linear regression analysis. CONCLUSIONS: Clinical diabetes is not associated with a change in endogenous AICAR levels. Loss of AICAR may therefore not be a mechanism by which AMPK signaling is reduced in diabetes.
Assuntos
Aminoimidazol Carboxamida/análogos & derivados , Diabetes Mellitus Tipo 2/urina , Ribonucleotídeos/urina , Adenilato Quinase/metabolismo , Adulto , Idoso , Aminoimidazol Carboxamida/urina , Animais , Estudos de Casos e Controles , Estudos de Coortes , Complicações do Diabetes/metabolismo , Complicações do Diabetes/prevenção & controle , Complicações do Diabetes/urina , Diabetes Mellitus Tipo 2/complicações , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/prevenção & controle , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estado Pré-Diabético/patologia , Estado Pré-Diabético/terapia , Estado Pré-Diabético/urina , Fatores de Risco , Comportamento de Redução do Risco , Transdução de Sinais/fisiologiaRESUMO
The high sensitivity of ultra high performance liquid chromatography coupled with high resolution mass spectrometry (UHPLC-HRMS) allows the identification of many prohibited substances without pre-concentration, leading to the development of simple and fast 'dilute-and-shoot' methods for doping control for human and equine sports. While the detection of polar drugs in plasma and urine is difficult using liquid-liquid or solid-phase extraction as these substances are poorly extracted, the 'dilute-and-shoot' approach is plausible. This paper describes a 'dilute-and-shoot' UHPLC-HRMS screening method to detect 46 polar drugs in equine urine and plasma, including some angiotensin-converting enzyme (ACE) inhibitors, sympathomimetics, anti-epileptics, hemostatics, the new doping agent 5-aminoimidazole-4-carboxamide-1-ß-d-ribofuranoside (AICAR), as well as two threshold substances, namely dimethyl sulfoxide and theobromine. For plasma, the sample (200µL) was protein precipitated using trichloroacetic acid, and the resulting supernatant was diluted using Buffer A with an overall dilution factor of 3. For urine, the sample (20µL) was simply diluted 50-fold with Buffer A. The diluted plasma or urine sample was then analysed using a UHPLC-HRMS system in full-scan ESI mode. The assay was validated for qualitative identification purpose. This straightforward and reliable approach carried out in combination with other screening procedures has increased the efficiency of doping control analysis in the laboratory. Moreover, since the UHPLC-HRMS data were acquired in full-scan mode, the method could theoretically accommodate an unlimited number of existing and new doping agents, and would allow a retrospectively search for drugs that have not been targeted at the time of analysis.
Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Dopagem Esportivo/prevenção & controle , Cavalos/sangue , Cavalos/urina , Espectrometria de Massas/métodos , Preparações Farmacêuticas/sangue , Preparações Farmacêuticas/urina , Detecção do Abuso de Substâncias/métodos , Aminoimidazol Carboxamida/análogos & derivados , Aminoimidazol Carboxamida/sangue , Aminoimidazol Carboxamida/urina , Animais , Ribonucleotídeos/sangue , Ribonucleotídeos/urinaRESUMO
In the field of LC-MS, reversed phase liquid chromatography is the predominant method of choice for the separation of prohibited substances from various classes in sports drug testing. However, highly polar and charged compounds still represent a challenging task in liquid chromatography due to their difficult chromatographic behavior using reversed phase materials. A very promising approach for the separation of hydrophilic compounds is hydrophilic interaction liquid chromatography (HILIC). Despite its great potential and versatile advantages for the separation of highly polar compounds, HILIC is up to now not very common in doping analysis, although most manufacturers offer a variety of HILIC columns in their portfolio. In this study, a novel multi-target approach based on HILIC high resolution/high accuracy mass spectrometry is presented to screen for various polar stimulants, stimulant sulfo-conjugates, glycerol, AICAR, ethyl glucuronide, morphine-3-glucuronide, and myo-inositol trispyrophosphate after direct injection of diluted urine specimens. The usage of an effective online sample cleanup and a zwitterionic HILIC analytical column in combination with a new generation Hybrid Quadrupol-Orbitrap® mass spectrometer enabled the detection of highly polar analytes without any time-consuming hydrolysis or further purification steps, far below the required detection limits. The methodology was fully validated for qualitative and quantitative (AICAR, glycerol) purposes considering the parameters specificity; robustness (rRT < 2.0%); linearity (R > 0.99); intra- and inter-day precision at low, medium, and high concentration levels (CV < 20%); limit of detection (stimulants and stimulant sulfo-conjugates < 10 ng/mL; norfenefrine; octopamine < 30 ng/mL; AICAR < 10 ng/mL; glycerol 100 µg/mL; ETG < 100 ng/mL); accuracy (AICAR 103.8-105.5%, glycerol 85.1-98.3% at three concentration levels) and ion suppression/enhancement effects.
Assuntos
Estimulantes do Sistema Nervoso Central/urina , Cromatografia Líquida/métodos , Detecção do Abuso de Substâncias/métodos , Espectrometria de Massas em Tandem/métodos , Urinálise/métodos , Aminoimidazol Carboxamida/análogos & derivados , Aminoimidazol Carboxamida/urina , Cromatografia Líquida/instrumentação , Dopagem Esportivo , Desenho de Equipamento , Feminino , Glucuronatos/urina , Glicerol/urina , Humanos , Interações Hidrofóbicas e Hidrofílicas , Hipoglicemiantes/urina , Fosfatos de Inositol/urina , Limite de Detecção , Masculino , Derivados da Morfina/urina , Ribonucleotídeos/urina , Detecção do Abuso de Substâncias/instrumentação , Espectrometria de Massas em Tandem/instrumentação , Urinálise/instrumentaçãoRESUMO
RATIONALE: AICAR (5-aminoimidazole-4-carboxamide 1ß-D-ribofuranoside) is prohibited in sport according to rules established by the World Anti-Doping Agency. Doping control laboratories identify samples where AICAR abuse is suspected by measuring its urinary concentration and comparing the observed level with naturally occurring concentrations. As the inter-individual variance of urinary AICAR concentrations is large, this approach requires a complementary method to unambiguously prove the exogenous origin of AICAR. Therefore, a method for the determination of carbon isotope ratios (CIRs) of urinary AICAR has been developed and validated. METHODS: Concentrated urine samples were fractionated by means of liquid chromatography for analyte cleanup. Derivatization of AICAR yielding the trimethylsilylated analog was necessary to enable CIR determinations by gas chromatography/combustion/isotope ratio mass spectrometry. The method was tested for its repeatability and stability over time and a linear mixing model was applied to test for possible isotopic discrimination. A reference population of n = 63 males and females was investigated to calculate appropriate reference limits to differentiate endogenous from exogenous urinary AICAR. These limits were tested by an AICAR elimination study. RESULTS: The developed method fulfills all the requirements for adequate sports drug testing and was found to be fit for purpose. The investigated reference population showed a larger variability in the CIR of AICAR than of the endogenous steroids. Nevertheless, the calculated thresholds for differences between AICAR and endogenous steroids can be applied straightforwardly to evaluate suspicious doping control samples with the same statistical confidence as established e.g. for testosterone misuse. These thresholds enabled the detection of a single oral AICAR administration for more than 40 h. CONCLUSIONS: Determination of thee CIRs is the method of choice to distinguish between an endogenous and an exogenous source of urinary AICAR. The developed method will enable investigations into doping control samples with elevated urinary concentrations of AICAR and clearly differentiate between naturally produced/elevated and illicitly administered AICAR.
Assuntos
Aminoimidazol Carboxamida/análogos & derivados , Isótopos de Carbono/análise , Cromatografia Gasosa-Espectrometria de Massas/métodos , Ribonucleotídeos/urina , Adulto , Aminoimidazol Carboxamida/urina , Dopagem Esportivo , Feminino , Cromatografia Gasosa-Espectrometria de Massas/instrumentação , Humanos , Masculino , Pessoa de Meia-Idade , Adulto JovemRESUMO
OBJECTIVES: Adenylosuccinate lyase deficiency (dADSL) is a rare inherited metabolic disorder. Biochemical diagnosis of the disease is based on the determination of enormously elevated urinary levels of succinylaminoimidazole carboxamide riboside (SAICA-riboside) and succinyladenosine (SAdo). We report a case of false negative screening for dADSL caused by deribosylation of the urinary biomarkers SAICA-riboside and SAdo. DESIGN AND METHODS: A thin-layer chromatography (TLC) method with Pauly reagent detection of SAICA-riboside was used as a screening method. High-performance liquid chromatography with diode-array detection (HPLC-DAD) and LC-MS/MS methods were used for the identification and quantitative determination of SAICA-riboside, SAdo, succinylaminoimidazole carboxamide (SAICA) and succinyladenine (SA). RESULTS: Following a negative TLC screening in a known case of dADSL, we analyzed urine using HPLC-DAD. The concentration of SAICA-riboside was 2.7mmol/mol creatinine (below the TLC detection limit), and we detected the two abnormal metabolites identified by LC-MS/MS as SAICA and SA. We showed that SAICA and SA were produced by deribosylation of SAICA-riboside and SAdo in the patient's urine. Studies performed by monitoring the production of SAICA and SA after the addition of SAICA-riboside and SAdo to the patient's urine and to urine samples from patients with urinary tract infections suggested that deribosylation is facilitated by bacterial enzymes. CONCLUSIONS: Screening methods for the diagnosis of dADSL may be falsely negative due to bacteria-mediated deribosylation of SAICA-riboside and SAdo. HPLC-DAD or LC-MS/MS analyses allowing for simultaneous detection of SAICA-riboside, SAdo and their deribosylation products SAICA and SA should be preferentially used for the diagnosis of dADSL in urine.
Assuntos
Adenilossuccinato Liase/deficiência , Aminoimidazol Carboxamida/análogos & derivados , Erros Inatos do Metabolismo da Purina-Pirimidina/diagnóstico , Erros Inatos do Metabolismo da Purina-Pirimidina/urina , Ribonucleosídeos/urina , Adenosina/análogos & derivados , Adenosina/urina , Adenilossuccinato Liase/urina , Aminoimidazol Carboxamida/metabolismo , Aminoimidazol Carboxamida/urina , Transtorno Autístico , Proteínas de Bactérias/metabolismo , Pré-Escolar , Cromatografia Líquida de Alta Pressão , Cromatografia em Camada Fina/métodos , Enterococcus faecalis , Enzimas/metabolismo , Reações Falso-Negativas , Humanos , Klebsiella pneumoniae , Ribonucleosídeos/metabolismo , Espectrometria de Massas em Tandem/métodos , Urina/microbiologiaRESUMO
BACKGROUND: There is currently a lack of reliable information on the exposures of residents and bystanders to pesticides in the UK. Previous research has shown that the methods currently used for assessing pesticide exposure for regulatory purposes are appropriate for farm workers 1. However, there were indications that the exposures of bystanders may sometimes be underestimated. The previous study did not collect data for residents. Therefore, this study aims to collect measurements to determine if the current methods and tools are appropriate for assessing pesticide exposure for residents living near agricultural fields. METHODS/DESIGN: The study will recruit owners of farms and orchards (hereafter both will be referred to as farms) that spray their agricultural crops with certain specified pesticides, and which have residential areas in close proximity to these fields. Recruited farms will be asked to provide details of their pesticide usage throughout the spray season. Informed consenting residents (adults (18 years and over) and children (aged 4-12 years)) will be asked to provide urine samples and accompanying activity diaries during the spraying season and in addition for a limited number of weeks before/after the spray season to allow background pesticide metabolite levels to be determined. Selected urine samples will be analysed for the pesticide metabolites of interest. Statistical analysis and mathematical modelling will use the laboratory results, along with the additional data collected from the farmers and residents, to determine systemic exposure levels amongst residents. Surveys will be carried out in selected areas of the United Kingdom over two years (2011 and 2012), covering two spraying seasons and the time between the spraying seasons. DISCUSSION: The described study protocol was implemented for the sample and data collection procedures carried out in 2011. Based on experience to date, no major changes to the protocol are anticipated for the 2012 spray season although the pesticides and regional areas for inclusion in 2012 are still to be confirmed.
Assuntos
Agricultura/métodos , Exposição Ambiental/análise , Praguicidas/urina , Adolescente , Adulto , Aminoimidazol Carboxamida/análogos & derivados , Aminoimidazol Carboxamida/urina , Captana/urina , Criança , Pré-Escolar , Clormequat/urina , Clorpirifos/urina , Diquat/urina , Monitoramento Ambiental/métodos , Humanos , Hidantoínas/urina , Nitrilas/urina , Piretrinas/urina , Medição de Risco , Estações do Ano , Tiofanato/urina , Triazóis/urina , Reino UnidoRESUMO
Influencing the endurance in elite sports is one of the key points in modern sports science. Recently, a new class of prohibited substances reached in the focus of doping control laboratories and their misuse was classified as gene doping. The adenosine monophosphate activated protein kinase activator 5-amino-4-imidazolecarboxyamide ribonucleoside (AICAR) was found to significantly enhance the endurance even in sedentary mice after treatment. Due to endogenous production of AICAR in healthy humans, considerable amounts were present in the circulation and, thus, were excreted into urine. Considering these facts, the present study was initiated to fix reference values of renally cleared AICAR in elite athletes. Therefore a quantitative analytical method by means of isotope-dilution liquid chromatography (analytical column: C6-phenyl) coupled to tandem mass spectrometry, after a sample preparation consisting of a gentle dilution of native urine, was developed. Doping control samples of 499 athletes were analysed, and AICAR concentrations in urine were determined. The mean AICAR value for all samples was 2,186 ng/mL with a standard deviation of 1,655 ng/mL. Concentrations were found to differ depending on gender, type of sport and type of sample collection (in competition/out of competition). The method was fully validated for quantitative purposes considering the parameters linearity, inter- (12%, 7% and 10%) and intraday precision (14%, 9% and 12%) at low, mid and high concentration, robustness, accuracy (approx. 100%), limit of quantification (100 ng/mL), stability and ion suppression effects, employing an in-house synthesised (13)C(5)-labelled AICAR as internal standard.
Assuntos
Aminoimidazol Carboxamida/análogos & derivados , Dopagem Esportivo , Ribonucleotídeos/urina , Aminoimidazol Carboxamida/urina , Feminino , Humanos , Masculino , Estrutura Molecular , Espectrometria de Massas em TandemRESUMO
Adenylosuccinate lyase (ADSL) deficiency is an inherited metabolic disorder affecting predominantly the central nervous system. The disease is characterized by the accumulation of succinylaminoimidazolecarboxamide riboside and succinyladenosine (S-Ado) in tissue and body fluids. Three children presented with muscular hypotonia, psychomotor delay, behavioral abnormalities, and white matter changes on brain MRI. Two of them were affected by seizures. Screening for inborn errors of metabolism including in vitro high resolution proton MRS revealed an ADSL deficiency that was confirmed genetically in all cases. All patients were studied by in vivo proton MRS. In vitro high resolution proton MRS of patient cerebrospinal fluid showed singlet resonances at 8.27 and 8.29 ppm that correspond to accumulated S-Ado. In vivo proton MRS measurements also revealed a prominent signal at 8.3 ppm in gray and white matter brain regions of all patients. The resonance was undetectable in healthy human brain. In vivo proton MRS provides a conclusive finding in ADSL deficiency and represents a reliable noninvasive diagnostic tool for this neurometabolic disorder.
Assuntos
Adenilossuccinato Liase/deficiência , Prótons , Erros Inatos do Metabolismo da Purina-Pirimidina/diagnóstico , Erros Inatos do Metabolismo da Purina-Pirimidina/enzimologia , Aminoimidazol Carboxamida/análogos & derivados , Aminoimidazol Carboxamida/líquido cefalorraquidiano , Aminoimidazol Carboxamida/urina , Criança , Pré-Escolar , Feminino , Humanos , Concentração de Íons de Hidrogênio , Lactente , Recém-Nascido , Imageamento por Ressonância Magnética , Espectroscopia de Ressonância Magnética , Masculino , Erros Inatos do Metabolismo da Purina-Pirimidina/líquido cefalorraquidiano , Erros Inatos do Metabolismo da Purina-Pirimidina/urina , Ribonucleotídeos/líquido cefalorraquidiano , Ribonucleotídeos/urina , S-Adenosilmetionina/líquido cefalorraquidiano , S-Adenosilmetionina/urinaRESUMO
Most cases of adenylosuccinate lyase (ADSL OMIM 103050) deficiency reported to date are confined to the various European ethnic groups. We report on the first Malaysian case of ADSL deficiency, which appears also to be the first reported Asian case. The case was diagnosed among a cohort of 450 patients with clinical features of psychomotor retardation, global developmental delay, seizures, microcephaly and/or autistic behaviour. The patient presented with frequent convulsions and severe myoclonic jerk within the first few days of life and severe psychomotor retardation. The high performance liquid chromatography (HPLC) profile of the urine revealed the characteristic biochemical markers of succinyladenosine (S-Ado) and succinyl-aminoimidazole carboximide riboside (SAICAr). The urinary S-Ado/SAICAr ratio was found to be 1.02 (type I ADSL deficiency). The patient was compound heterozygous for two novel mutations, c.445C > G (p.R149G) and c.774_778insG (p.A260GfsX24).
Assuntos
Monofosfato de Adenosina/análogos & derivados , Adenilossuccinato Liase/deficiência , Análise Mutacional de DNA , Testes Genéticos/métodos , Mutação , Erros Inatos do Metabolismo da Purina-Pirimidina/diagnóstico , Erros Inatos do Metabolismo da Purina-Pirimidina/genética , Adenosina/análogos & derivados , Adenosina/urina , Monofosfato de Adenosina/deficiência , Monofosfato de Adenosina/genética , Adenilossuccinato Liase/genética , Aminoimidazol Carboxamida/análogos & derivados , Aminoimidazol Carboxamida/urina , Transtorno Autístico , Biomarcadores/urina , Desenvolvimento Infantil , Cromatografia Líquida de Alta Pressão , Predisposição Genética para Doença , Heterozigoto , Humanos , Lactente , Recém-Nascido , Malásia , Masculino , Mioclonia/diagnóstico , Mioclonia/genética , Fenótipo , Valor Preditivo dos Testes , Transtornos Psicomotores/diagnóstico , Transtornos Psicomotores/genética , Desempenho Psicomotor , Erros Inatos do Metabolismo da Purina-Pirimidina/complicações , Erros Inatos do Metabolismo da Purina-Pirimidina/enzimologia , Ribonucleosídeos/urina , Convulsões/diagnóstico , Convulsões/genética , Espectrometria de Massas por Ionização por Electrospray , Espectrometria de Massas em TandemRESUMO
Adenylosuccinate lyase deficiency is a rare autosomal disorder of de novo purine synthesis, which results in the accumulation of succinylpurines in body fluids. Patients with adenylosuccinate lyase deficiency show a variable combination of mental retardation, epilepsy and autistic features and are usually discovered during screens for unexplained encephalopathy using the Bratton-Marshall assay that reveals the excretion of the succinylaminoimidazolecarboxamide riboside (SAICAr). Here, we report on two sisters aged 11 and 12 years presented with global developmental delay, motor apraxia, severe speech deficits, seizures and behavioural features, which combined excessive laughter, a very happy disposition, hyperactivity, a short attention span, the mouthing of objects, tantrums and stereotyped movements that gave a behavioural profile mimicking Angelman syndrome. Both patients had an increased succinyladenosine/SAICAr ratio of 1.6, and exhibited a novel homozygous missense mutation (c.674T>C; p.Met225Thr) in the exon 6 of the ADSL gene. We suggest that these clinical features might be a new presentation of adenylosuccinate lyase deficiency. On the basis of this observation, although adenylosuccinate lyase deficiency is a rare disorder, this diagnosis should be considered in patients with mental retardation and a behavioural profile suggestive of Angelman syndrome.
Assuntos
Adenilossuccinato Liase/deficiência , Adenilossuccinato Liase/genética , Comportamento , Deficiência Intelectual/genética , Erros Inatos do Metabolismo da Purina-Pirimidina/genética , Adenosina/análogos & derivados , Adenosina/urina , Aminoimidazol Carboxamida/análogos & derivados , Aminoimidazol Carboxamida/urina , Síndrome de Angelman/diagnóstico , Criança , Cromatografia Líquida de Alta Pressão , Consanguinidade , Feminino , Humanos , Deficiência Intelectual/psicologia , Mutação de Sentido Incorreto , Linhagem , Fenótipo , Erros Inatos do Metabolismo da Purina-Pirimidina/diagnóstico , Erros Inatos do Metabolismo da Purina-Pirimidina/psicologia , Ribonucleotídeos/urina , Análise de Sequência de DNA , Comportamento EstereotipadoRESUMO
Deficiency of adenylosuccinate lyase (ADSL) (OMIM 103050) is an autosomal recessive disorder of the purine de novo synthesis pathway and purine nucleotide cycle, diagnosed so far in approximately 50 patients. The clinical presentation is characterized by severe neurological involvement including hypotonia, seizures, developmental delay and autistic features. Epilepsy in ADSL deficiency is frequent and occurs in approximately two-thirds of patients, beginning either early in the neonatal period or after the first year of life. At present there is no treatment of proven clinical efficacy. Despite of the increasing number of ADSL-deficient patients reported, there are only a few communications of therapeutic considerations or efforts. Among them only two showed some beneficial effects in ADSL-deficient patients. D-ribose, a simple and relatively cheap therapy, has been associated with improvement of behaviour and progressive reduction of the seizure frequency in one 13-year-old patient with ADSL deficiency. In this study we have re-examined D-ribose treatment in four ADSL-deficient patients. Assessments consisted of biochemical markers and neurological outcome. The 12-month trial of D-ribose failed to show any clinical benefit in ADSL patients with both milder and severe phenotype. D-ribose administration was accompanied by neither reduction in seizure frequency nor growth enhancement. Additionally, patients with milder type II presented the first seizure after 4 and 8 months of the D-ribose treatment. Therefore, we could not confirm a positive effect of D-ribose as previously reported.
Assuntos
Adenilossuccinato Liase/deficiência , Transtornos do Crescimento/prevenção & controle , Ribose/uso terapêutico , Convulsões/prevenção & controle , Adenosina/análogos & derivados , Adenosina/urina , Adenilossuccinato Liase/efeitos dos fármacos , Aminoimidazol Carboxamida/análogos & derivados , Aminoimidazol Carboxamida/urina , Transtorno Autístico , Glicemia/metabolismo , Criança , Pré-Escolar , Creatinina/urina , Feminino , Transtornos do Crescimento/enzimologia , Transtornos do Crescimento/etiologia , Humanos , Polônia , Erros Inatos do Metabolismo da Purina-Pirimidina/complicações , Erros Inatos do Metabolismo da Purina-Pirimidina/diagnóstico , Erros Inatos do Metabolismo da Purina-Pirimidina/enzimologia , Ribonucleosídeos/urina , Convulsões/enzimologia , Convulsões/etiologia , Índice de Gravidade de Doença , Falha de Tratamento , Ácido Úrico/sangueRESUMO
The objectives were: (1) to test the association of methotrexate (MTX) efficacy in rat adjuvant arthritis (rat AA) with interference of purine biosynthesis and adenosine metabolism and (2) to test the efficacy of erythro-9-(2-hydroxynon-3-yl) adenine (EHNA), an inhibitor of adenosine deaminase, and the efficacy of aminoimidazolecarboxamide (AICA) riboside plus MTX in rat AA. Radiographic and histologic examinations of the hind limbs were measures of efficacy. Urinary excretions of AICA and adenosine were markers of AICA ribotide transformylase inhibition (i.e., blockage of purine biosynthesis) and interference with adenosine metabolism, respectively. AICA and adenosine excretions increased during the day of MTX dosing (treatment day) compared to the previous baseline day in animals responding well to MTX (i.e., low radiographic and histologic scores). Based on radiographic and histologic scores, adjuvant injected rats were separated into two disease categories (i.e., no/mild and moderate/severe). Only AICA excretion was significantly elevated on the treatment day in rat AA with no/mild disease (i.e., those responding well to MTX therapy). AICA (not adenosine) excretion was significantly correlated with the above scores. EHNA was not efficacious, even at toxic levels, while AICA riboside potentiated the efficacy of MTX. The data suggests that efficacious MTX therapy in rat AA (1) blocks purine biosynthesis; (2) increases in in vivo AICA levels. Also adenosine accumulation and blockage of adenosine deaminase (i.e., by EHNA) appear to be less critical to MTX efficacy. Increased levels of AICA metabolites may suppress the immune response in rat AA.
Assuntos
Adenina/análogos & derivados , Aminoimidazol Carboxamida/análogos & derivados , Antirreumáticos/farmacologia , Artrite Experimental/tratamento farmacológico , Inibidores Enzimáticos/farmacologia , Metotrexato/farmacologia , Purinas/metabolismo , Ribonucleosídeos/farmacologia , Adenina/farmacologia , Adenina/uso terapêutico , Adenosina/urina , Adenosina Desaminase/metabolismo , Inibidores de Adenosina Desaminase , Aminoimidazol Carboxamida/farmacologia , Aminoimidazol Carboxamida/uso terapêutico , Aminoimidazol Carboxamida/urina , Animais , Antirreumáticos/uso terapêutico , Artrite Experimental/enzimologia , Artrite Experimental/patologia , Artrite Experimental/urina , Biomarcadores/urina , Relação Dose-Resposta a Droga , Quimioterapia Combinada , Inibidores Enzimáticos/uso terapêutico , Metotrexato/uso terapêutico , Fosforribosilaminoimidazolcarboxamida Formiltransferase/antagonistas & inibidores , Fosforribosilaminoimidazolcarboxamida Formiltransferase/metabolismo , Purinas/urina , Ratos , Ribonucleosídeos/uso terapêuticoRESUMO
The fungicides vinclozolin and iprodione are widely used in agriculture. These pesticides are dicarboximide fungicides containing the common moiety 3,5-dichloroaniline (3,5-DCA). It has been suggested that low-level exposures to such compounds may be associated with adverse health effects such as endocrine disruption. In this study a method using liquid chromatography/triple quadrupole mass spectrometry (LC/MS/MS) was developed for the analysis of 3,5-DCA as a biomarker of exposure to these fungicides in human urine. The urine samples were treated by basic hydrolysis to degrade the fungicides, their metabolites and conjugates to 3,5-DCA. The 3,5-DCA was then extracted using toluene and derivatized using pentafluoropropionic anhydride (PFPA). Analysis of the derivative was carried out using selected reaction monitoring (SRM) in the negative ion mode. Quantification of the derivative was performed using [(13)C(6)]-labeled 3,4-DCA as an internal standard with good precision and linearity in the range 0.1-200 ng/mL urine. The limit of detection was determined to be 0.1 ng/mL. The metabolites in urine were found to be stable during storage at -20 degrees C. To validate 3,5-DCA as a biomarker the method was applied in a human experimental exposure to iprodione and vinclozolin. Two healthy volunteers received 200 microg single oral doses of each pesticide followed by urine sampling during 72-120 h post-exposure. Between 78-107% of the dose was recovered as 3,5-DCA in the urine after exposure.
Assuntos
Aminoimidazol Carboxamida/análogos & derivados , Compostos de Anilina/urina , Fungicidas Industriais/farmacocinética , Hidantoínas/farmacocinética , Oxazóis/farmacocinética , Espectrometria de Massas por Ionização por Electrospray/métodos , Adulto , Aminoimidazol Carboxamida/farmacocinética , Aminoimidazol Carboxamida/urina , Biomarcadores/urina , Cromatografia Líquida de Alta Pressão , Exposição Ambiental/análise , Feminino , Fungicidas Industriais/urina , Humanos , Hidantoínas/urina , Masculino , Pessoa de Meia-Idade , Oxazóis/urina , Espectrometria de Massas em TandemRESUMO
AICA-ribosiduria is a recently discovered inherited metabolic disease caused by a defect in final steps of purine de novo biosynthesis-5-amino-4-imidazolecarboxamide ribotide (AICAR)-transformylase/inosinemonophosphate (IMP)-cyclohydrolase (ATIC). A rapid and selective capillary electrophoretic method for screening of patients with AICA-ribosiduria is described. The method is based on direct ultraviolet detection of 5-amino-4-imidazolecarboxamide (AICA) and 5-amino-4-imidazolecarboxamide riboside (AICAr) in untreated urine. Background electrolyte consists of 100mM malonic acid adjusted with gamma-aminobutyric acid (pH 2.7). Under the given separation conditions both compounds of interest are well separated from other substances with separation efficiency of 1020000 and 130000 theoretical plates/m for AICA and AICAr, respectively. Total analysis time is 3 min with the limits of detection of 3.6 microM and 4.5 microM for AICA and AICAr, respectively. The usefulness of the presented method for screening of patients with ATIC deficiency is demonstrated on samples of Chinese hamster ovary cell line defective in ATIC activity, spiked urine samples and urine samples from patients treated with high-dose MTX which do not excrete increased amounts of AICA and AICAr compared to untreated controls (p<0.05). The described method is fast and effective enough for diagnostic applications.
Assuntos
Aminoimidazol Carboxamida/análogos & derivados , Eletroforese Capilar/métodos , Erros Inatos do Metabolismo/diagnóstico , Ribonucleosídeos/urina , Adulto , Aminoimidazol Carboxamida/urina , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
A method based on solid-phase extraction (SPE) and high-performance liquid chromatography (HPLC) was developed for the simultaneous determination of 3-(3,5-diclorophenyl)-5-ethenyl-5-methyl-2,4-oxazolidinedione (vinclozolin) and 3-(3,5-diclorophenyl)-N-(1-methylethyl)-2,4-dioxo-1-imidazolidinecarboxamide (iprodione) in human urine. Urine samples containing vinclozolin and iprodione were collected by solid phase extraction using C(18) cartridges. The chromatographic separation was achieved on a Spherisorb ODS2 (250 mm x 4.6 mm, 5 microm) column with an isocratic mobile phase of acetonitrile-water (60:40, v/v). Detection was UV absorbance at 220 nm. The calibration graphs were linear from 30 to 1000 ng/mL for the two fungicides. Intra- and inter-day R.S.D. did not exceed 2.9%. The quantitation limit was 50 ng/mL for vinclozolin and 30 ng/mL for iprodione, respectively.
Assuntos
Aminoimidazol Carboxamida/análogos & derivados , Cromatografia Líquida de Alta Pressão/métodos , Hidantoínas/urina , Oxazóis/urina , Reprodutibilidade dos Testes , Aminoimidazol Carboxamida/urina , Humanos , Xenobióticos/análise , Xenobióticos/químicaRESUMO
A deficiency of adenylosuccinate lyase (ASDL) is characterised by the accumulation of SAICAriboside (SAICAr) and succinyladenosine (S-Ado) in body fluids. The severity of the clinical presentation correlates with a low S-Ado/SAICAr ratio in body fluids. We report the first British case of ADSL deficiency. The patient presented at 14 days with a progressive neonatal encephalopathy and seizures. There was marked axial and peripheral hypotonia. Brain MRI showed widespread white matter changes. She died at 4 weeks of age. Concentrations of SAICAr and SAdo were markedly elevated in urine, plasma and CSF and the SAdo/SAICAr ratio was low, consistent with the severe phenotype. The patient was compound heterozygous for 2 novel ADSL mutations; c.9 G>C (A3P) and c.572 C>T (R190X).
Assuntos
Adenosina/análogos & derivados , Adenilossuccinato Liase/deficiência , Adenilossuccinato Liase/genética , Aminoimidazol Carboxamida/análogos & derivados , Erros Inatos do Metabolismo da Purina-Pirimidina/diagnóstico , Erros Inatos do Metabolismo da Purina-Pirimidina/genética , Adenosina/sangue , Adenosina/líquido cefalorraquidiano , Adenosina/urina , Aminoimidazol Carboxamida/sangue , Aminoimidazol Carboxamida/líquido cefalorraquidiano , Aminoimidazol Carboxamida/urina , Catálise , Éxons , Evolução Fatal , Feminino , Heterozigoto , Humanos , Recém-Nascido , Mutação , Fenótipo , Purinas/metabolismo , Ribonucleotídeos/sangue , Ribonucleotídeos/líquido cefalorraquidiano , Ribonucleotídeos/urinaRESUMO
OBJECTIVE: To determine if folinic acid supplementation during methotrexate (MTX) therapy for rheumatoid arthritis (RA) reduces both urinary 5-aminoimidazole-4-carboxamide (AICA) and urinary adenosine excretion more than does folic acid supplementation. AICA and adenosine are markers for MTX interference with purine metabolism. METHODS: Forty patients with RA who received MTX for 6 weeks were randomized to receive either daily folic acid or folinic acid supplements during an additional week of MTX therapy. Colorimetric and radioimmunocompetition assays were used to measure 24-hour urinary AICA and adenosine excretion levels, respectively. RESULTS: At the end of 6 weeks, 24-hour urinary levels of AICA, but not adenosine, were elevated as compared with baseline levels (i.e., prior to MTX therapy). Folinic acid, but not folic acid, supplementation normalized urinary AICA levels during MTX therapy. Relatively high urinary levels of AICA were correlated with reduced disease activity. No similar correlations were seen with urinary adenosine levels. CONCLUSION: The blockade of purine nucleotide biosynthesis by MTX at the AICA ribonucleotide transformylase-catalyzed step may be related to the efficacy of MTX, and this blockade is effectively relieved by folinic acid, but not by folic acid, supplementation.
Assuntos
Aminoimidazol Carboxamida/análogos & derivados , Artrite Reumatoide/tratamento farmacológico , Artrite Reumatoide/metabolismo , Ácido Fólico/administração & dosagem , Leucovorina/administração & dosagem , Metotrexato/uso terapêutico , Purinas/metabolismo , Adenosina/urina , Aminoimidazol Carboxamida/urina , Eritrócitos/química , Feminino , Ácido Fólico/sangue , Homocisteína/sangue , Humanos , Masculino , Pessoa de Meia-Idade , Piridoxina/administração & dosagem , Ribonucleotídeos/urina , Resultado do Tratamento , Vitamina B 12/administração & dosagemRESUMO
We report on the striking variable expression of adenylosuccinate lyase (ADSL) deficiency in three patients belonging to a family which originates from Portugal. ADSL deficiency is a rare autosomal recessive disorder of the de novo purine synthesis which results in accumulation of succinylpurines in body fluids. As a result, patients may have variable combinations of psychomotor retardation and/or regression, seizures, autistic features and cerebellar vermis hypoplasia. However, intrafamilial variable expression of the phenotype has not been documented to date in this disease and is not commonly observed in metabolic disorders. Here, while the proband had marked psychomotor regression and progressive cerebellar vermis atrophy, the other two affected patients presented mainly autistic features. Mutation analysis of the ADSL gene revealed the presence of a homozygous R426H mutation in this family. Finally, although ADSL deficiency is a rare disorder, this diagnosis should be considered and assessed using a simple urinary screening method for the presence of succinylpurines in any patient with mental retardation of unexplained origin.